The year 2017 has been one of continued success for JAMA Psychiatry. The journal received ever-growing numbers of submissions but continued favorable patterns of timely and responsive handling of submitted manuscripts despite this larger volume. The number of major manuscripts we received reached 1313, an all-time high (Table). We reject more than two-thirds of submitted manuscripts without peer review because we have room to publish only 15% of all submissions. The fast median turnaround time to initial decision without peer review of 2 days allows authors to submit rejected manuscripts elsewhere as quickly as possible.
For manuscripts sent out for peer review, we strive to obtain timely reviews, make editorial decisions, and rapidly publish accepted manuscripts. In 2017, we saw improvements in both peer review turnaround time and acceptance to publication time compared with previous years. As in previous years, JAMA Psychiatry publishes all articles online first every Wednesday. If an author is scheduled to present results at an upcoming scientific meeting, we can arrange for a special release on the day of the presentation.
We thank all authors for their submissions and all our peers across the world who have helped with the review process. JAMA Psychiatry is known for scholarly peer reviews, and we remain committed to this tradition. See the link to “JAMA Psychiatry Peer Reviewers in 2017” for a complete list of the 831 peer reviewers.4
JAMA Psychiatry’s impact factor has increased to 15.3. It is now firmly established as a leading journal in the field under its new name while preserving the traditions of the Archives of General Psychiatry. In addition to the journal’s impact on scholarly output, we continue to benefit from the JAMA Network’s digital expansion strategy. Our number of Twitter followers has grown to 18 500 and Facebook followers to more than 21 000, while 54 000 individuals received our weekly electronic table of contents. More than 5 million full-text/PDF articles were downloaded from our website last year. One summary index we follow to gauge influence in news and social media is the Altmetric score. The 3 JAMA Psychiatry articles from 2017 with the highest Altmetric score are listed in the Table.1-3 In summary, JAMA Psychiatry now has a very robust and influential digital presence.
In 2017, we increased the number of clinical trials published in JAMA Psychiatry, and this is a trend we intend to continue. We will also continue to publish a series of neuroscience education pieces that combine a Clinical Challenge with a Review article explaining the relevant neuroscience for specific disease categories.
JAMA Psychiatry made significant progress under the leadership of Stephan Heckers, MD. He was assisted by managing editor Jenni Blackford, PhD; web editor Christine Konradi, PhD; statistical editor Helena Chmura Kraemer, PhD; editorial assistant Jennye Laws-Woolf; deputy editor Dost Öngür, MD, PhD; and associate editor Martin Paulus, MD. We are all thankful for the privilege of serving JAMA Psychiatry.
Corresponding Author: Dost Öngür, MD, PhD, Department of Psychiatry, Harvard Medical School, McLean Hospital, 115 Mill St, Mailstop 108, Room AB320, Belmont, MA 02478 (dongur@partners.org).
Published Online: March 14, 2018. doi:10.1001/jamapsychiatry.2017.4161
Conflict of Interest Disclosures: None reported.
1.Grant
BF, Chou
SP, Saha
TD,
et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
JAMA Psychiatry. 2017;74(9):911-923. doi:
10.1001/jamapsychiatry.2017.2161PubMedGoogle ScholarCrossref 3.Sanacora
G, Frye
MA, McDonald
W,
et al; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A consensus statement on the use of ketamine in the treatment of mood disorders.
JAMA Psychiatry. 2017;74(4):399-405. doi:
10.1001/jamapsychiatry.2017.0080PubMedGoogle ScholarCrossref